Regenxbio promotes Curran Simpson to CEO

Regenxbio announced that Curran Simpson, COO, has been appointed as President, CEO and a member of the Board of Directors, effective July 1. Co-Founder Kenneth T. Mills will step down as President and CEO following 15 years of leadership at the Company, and he is taking on an expanded role on the Board as Chairman. In connection with these changes, Board member Daniel Tasse has been appointed as REGENXBIO’s Lead Independent Director, a role previously held by Jerry Karabelas, Karabelas and Co-Founder Allan Fox, who has served as Chairman since 2020, will remain on the Board. Simpson is a seasoned biopharmaceuticals leader with over 35 years of industry experience. As the COO at REGENXBIO since January 2023, he has been directly responsible for key business functions including Research & Clinical Development, Corporate Strategy, Manufacturing & Quality, Regulatory, and Commercial Operations. Simpson joined REGENXBIO in 2015 and served as the Company’s Chief Technology and Operations Officer before becoming COO. Prior to joining REGENXBIO, he was the Regional Supply Chain Head for North America and Interim COO at GlaxoSmithKline. Simpson earlier served as interim CEO at Human Genome Sciences, where he led the integration of HGS into GSK.